__NUXT_JSONP__("/drugs/Decitabine", (function(a,b,c,d,e,f,g,h,i,j,k,l,m){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:a,conditionIndication:"Treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organization (WHO) classification, who are not candidates for standard induction chemotherapy.",inn:c,marketingAuthorisationDate:"2012-09-20 00:00:00",marketingAuthorisationHolder:"Janssen-Cilag International N.V.  ",medicineName:f,url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fdacogen"}],fdaDrugLabel:[{brand:g,indication:"1 INDICATIONS AND USAGE Decitabine for injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. Decitabine for injection is a nucleoside metabolic inhibitor indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.",manufacturer:"Nivagen Pharmaceuticals, Inc.",splSetId:"150537a8-10ac-422d-bf33-68b1a408e566"},{brand:a,indication:"1 INDICATIONS AND USAGE Decitabine for injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. Decitabine for injection is a nucleoside metabolic inhibitor indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high‑risk International Prognostic Scoring System groups. ( 1 )",manufacturer:i,splSetId:"18651e4f-398c-4889-b199-b92b2bd49568"},{brand:a,indication:"1 INDICATIONS AND USAGE Decitabine for injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. Decitabine for injection is a nucleoside metabolic inhibitor indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.( 1 )",manufacturer:j,splSetId:"1abbe952-58bc-4dbc-b06a-fb79167bcd66"},{brand:a,indication:d,manufacturer:k,splSetId:"358764ca-4c69-d516-af0c-bf8a348d26ca"},{brand:c,indication:b,manufacturer:"Gland Pharma Limited",splSetId:"39a26b24-e9d4-4974-9788-d025c51fc94f"},{brand:a,indication:b,manufacturer:"Amneal Pharmaceuticals LLC",splSetId:"40e7ef72-8df5-4adf-a269-4ae1c26eb6f9"},{brand:a,indication:h,manufacturer:"Mylan Institutional LLC",splSetId:"447a9fbd-106d-4ff6-8fd0-bb38a8c90e17"},{brand:a,indication:d,manufacturer:j,splSetId:"4730a57f-d04f-bcc3-ef35-1bfdd0284b4d"},{brand:a,indication:"1 INDICATIONS AND USAGE Decitabine for injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1,intermediate-2, and high-risk International Prognostic Scoring System groups. Decitabine for injection is a nucleoside metabolic inhibitor indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation , and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. ( 1 )",manufacturer:"Fresenius Kabi USA, LLC",splSetId:"4d568777-0946-489c-99bf-57e1f562e285"},{brand:a,indication:d,manufacturer:"Dr.Reddy's Laboratories Limited",splSetId:"4e1f4eb4-19b2-eee8-3402-bd2ccf622791"},{brand:a,indication:b,manufacturer:"Qilu Pharmaceutical Co., Ltd.",splSetId:"5b2dce6f-c715-47dc-971e-06244ccd7548"},{brand:a,indication:"1 INDICATIONS AND USAGE Decitabine for injection is a nucleoside metabolic inhibitor indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high‑risk International Prognostic Scoring System groups. ( 1 ) Decitabine for injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.",manufacturer:"NorthStar RxLLC",splSetId:"68896a75-74ce-42c3-a6a5-c6775d03a7ef"},{brand:a,indication:"1 INDICATIONS AND USAGE Decitabine for Injection is a nucleoside metabolic inhibitor indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. ( 1 ) Decitabine for Injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.",manufacturer:i,splSetId:"77a7ea8f-3037-4ca6-b605-e5d1df5e7422"},{brand:c,indication:"1 INDICATIONS AND USAGE Decitabine for injection is a nucleoside metabolic inhibitor indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1,intermediate-2, and high-risk International Prognostic Scoring System groups. ( 1 ) Decitabine for injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1,intermediate-2, and high-risk International Prognostic Scoring System groups.",manufacturer:"Lupin Pharmaceuticals, Inc.",splSetId:"79d5d5e3-f782-44e9-b422-664d9371647e"},{brand:"INQOVI",indication:"1 INDICATIONS AND USAGE INQOVI is indicated for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. INQOVI is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor, indicated for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. ( 1 )",manufacturer:"Taiho Pharmaceutical Co., Ltd.",splSetId:"91a0f80b-f865-4d06-a40d-4d148d99ee71"},{brand:a,indication:d,manufacturer:k,splSetId:"99cea19b-cabf-8a6d-b2ef-f04920952b93"},{brand:a,indication:e,manufacturer:l,splSetId:"a1b43089-bc88-4ac6-bdee-9cc38ec30f4e"},{brand:a,indication:e,manufacturer:"MSN LABORATORIES PRIVATE LIMITED",splSetId:"a3c1551a-41aa-4508-9d88-0210b2d4df78"},{brand:a,indication:b,manufacturer:"Meitheal Pharmaceuticals Inc.",splSetId:"a535a235-e1d2-4520-93fe-b7dd9b047784"},{brand:a,indication:h,manufacturer:"AuroMedics Pharma LLC",splSetId:"a99f92cf-88f9-469b-aa69-44831e0bd4ab"},{brand:a,indication:e,manufacturer:l,splSetId:"ae6c4580-3a3a-4c42-903a-1565d79521f8"},{brand:g,indication:b,manufacturer:"Ingenus Pharmaceuticals, LLC",splSetId:"b3a26585-e247-4b2e-a4ce-817b3aac2ff3"},{brand:a,indication:b,manufacturer:"Accord Healthcare Inc.",splSetId:"b46df7d7-d98e-4c7e-b1ee-e03e258781c4"},{brand:a,indication:h,manufacturer:"Wockhardt USA LLC.",splSetId:"c3218c35-c9fb-4bb9-9055-75a6585dfd2e"},{brand:a,indication:e,manufacturer:"Sandoz Inc",splSetId:"c75493fd-b64d-4ed4-8a5c-b78bad5dbc3d"},{brand:a,indication:b,manufacturer:"Athenex Pharmaceutical Division, LLC.",splSetId:"ccc5e993-f19e-423b-9cb7-7f0c3a5875aa"},{brand:f,indication:"1 INDICATIONS AND USAGE DACOGEN is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. DACOGEN is a nucleoside metabolic inhibitor indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. ( 1 )",manufacturer:"Otsuka America Pharmaceutical, Inc.",splSetId:"deb4a13c-855b-4372-9778-6e81da598df6"},{brand:c,indication:b,manufacturer:"Sagent Pharmaceuticals",splSetId:"e509b63e-a652-4d59-8d73-4d9be97e800c"},{brand:a,indication:"1 INDICATIONS AND USAGE Decitabine for Injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. Decitabine for injection is a nucleoside metabolic inhibitor indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. ( 1 )",manufacturer:"BluePoint Laboratories",splSetId:"fe7db776-87da-4984-b708-80b09f835e78"}],id:a,nciThesaurus:{casRegistry:"2353-33-5",chebiId:"CHEBI:50131",chemicalFormula:"C8H12N4O4",definition:"A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication.",fdaUniiCode:"776B62CQ27",identifier:"C981",preferredName:a,semanticType:"Nucleic Acid, Nucleoside, or Nucleotide",subclassOf:[],synonyms:["2'-Deoxy-5-azacytidine","4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one","5-Aza-2'-deoxycytidine","5-Aza-2'deoxycytidine","5-Aza-2-deoxycytidine","5-Azadeoxycytidine",g,f,a,"Decitabine for Injection","Deoxyazacytidine","Dezocitidine",c]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FDecitabine",extension:".json",createdAt:m,updatedAt:m}}],fetch:{},mutations:void 0}}("Decitabine","1 INDICATIONS AND USAGE Decitabine for Injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. Decitabine for Injection is a nucleoside metabolic inhibitor indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. ( 1 )","decitabine","1 INDICATIONS AND USAGE Decitabine for injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. Decitabine For Injection is a nucleoside metabolic inhibitor indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate2, and high-risk International Prognostic Scoring System groups","1 INDICATIONS AND USAGE Decitabine for injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. Decitabine for injection is a nucleoside metabolic inhibitor indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, Intermediate-2, and high-risk International Prognostic Scoring System groups.( 1 )","Dacogen","DECITABINE","1 INDICATIONS AND USAGE Decitabine for injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. Decitabine for injection is a nucleoside metabolic inhibitor indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. ( 1 )","Cipla USA Inc.","Northstar Rx LLC","Dr. Reddy's Laboratories Inc.","Novadoz Pharmaceuticals LLC","2021-10-30T13:48:48.503Z")));